Martin L. Heubner

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Salivary microRNA testing for endometriosis: clinical evaluation in an endometriosis center.

Salivary microRNA testing for endometriosis: clinical evaluation in an endometriosis center.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: April 12, 2026

Multicenter evaluation of the DEXTER® Robotic Surgery System for Total Hysterectomy with Adnexal Surgery.

Multicenter evaluation of the DEXTER® Robotic Surgery System for Total Hysterectomy with Adnexal Surgery.

Journal: Journal of robotic surgery

Published: June 24, 2025

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 04, 2022

p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.

p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.

Journal: American journal of obstetrics and gynecology

Published: October 09, 2020

Suspensory Ligaments of the Female Genital Organs: MRI Evaluation with Intraoperative Correlation.

Suspensory Ligaments of the Female Genital Organs: MRI Evaluation with Intraoperative Correlation.

Journal: Radiographics : a review publication of the Radiological Society of North America, Inc

Published: November 14, 2018

Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.

Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancer.

Journal: Future science OA

Published: May 17, 2016

Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system.

Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system.

Journal: Gynecologic oncology reports

Published: January 22, 2016

Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG).

Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG).

Journal: Journal of surgical oncology

Published: December 03, 2015

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Journal: Gynecologic oncology

Published: October 29, 2015

Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.

Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.

Journal: Archives of gynecology and obstetrics

Published: September 15, 2015

B3-lesions of the breast and cancer risk - an analysis of mammography screening patients.

B3-lesions of the breast and cancer risk - an analysis of mammography screening patients.

Journal: Molecular and clinical oncology

Published: September 08, 2015

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Journal: The Lancet. Oncology

Published: July 24, 2015

Showing 1-12 of 32

Last Updated: 09/26/2026